Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem. Pfizer offers a high dividend yield and lots of upside potential.

They selected healthcare companies AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and Pfizer (NYSE: PFE). Here's why. Keith Speights (AbbVie): You can count the number of Dividend Kings that operate in ...

Pfizer has not launched any digital treatments ... detailed data showing that its experimental lung cancer therapy beat Merck’s blockbuster Keytruda in a late-stage trial. That study was ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at ...

Merck's revenue and earnings continue to grow ... The company is an excellent income stock to buy and hold. Pfizer is a high-yielding stock with a lot of upsides David Jagielski (Pfizer): One ...

Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV ® and KEYTRUDA ® in patients with previously untreated metastatic urothelial cancer.

Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not ...